PROPRANOLOL MARKET

INTRODUCTION

The pharmaceutical propranolol, also marketed under the name Inderal, is a member of the beta-blocker group of medications.

It is mostly used to treat cardiac rhythm problems, excessive blood pressure, and other cardiovascular diseases like angina and heart failure. It functions by preventing the heart and blood arteries from being affected by the hormone adrenaline, which can lower blood pressure and lessen the strain on the heart.

Propranolol has been used off-label to treat anxiety, stage fright, migraines, and tremors in addition to its cardiovascular applications. Some forms of glaucoma may also be treated with it.

Like other medicines, propranolol may have unwanted effects, some of which include low blood pressure, depression, sexual dysfunction, lethargy, dizziness, and low blood pressure.

It should be taken with caution in patients with asthma or other respiratory disorders since it may also hide the signs of low blood sugar in diabetics. 

PROPRANOLOL MARKET SIZE AND FORECAST

Global Propranolol market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

PROPRANOLOL MARKETRECENT DEVELOPMENTS 

Propranolol has recently gained interest for its ability to treat children's PTSD symptoms. Randomized clinical trials are necessary, nonetheless, to verify its efficacy.

Additionally, as they may reduce the longevity of patients with cirrhosis, nonselective beta-blockers like propranolol should be stopped or avoided in patients with intractable ascites.

Although propranolol is typically well taken, it can have unwanted effects like vivid or strange nightmares, angina flare-ups, and in rare cases, heart attacks. Elderly individuals could be more vulnerable to these consequences.

COVID-19 IMPACT

Inflammation is one of the many abnormalities that COVID-19 patients experience because the SARS-CoV-2 virus compromises the immune system. Beta-blockers may assist to lessen this inflammation and restore the immune system's balance.

A common beta-blocker called metoprolol may be helpful in treating COVID-induced ARDS, according to a study that was published in the Journal of the American College of Cardiology.

COVID-19 patients with ARDS were randomised to receive metoprolol medication or to be in a control group that got no further care.The findings imply that metoprolol may be a straightforward and affordable treatment for ARDS in COVID patients.

PROPRANOLOL MARKETCOMPANY PROFILE

• AstraZeneca
• Teva Pharmaceuticals
• Pfizer
• Mylan
• Sandoz
• Apotex
• Watson Pharmaceuticals
• Actavis
• Sun Pharmaceutical Industries
• Glenmark Pharmaceuticals

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS OFPROPRANOLOL MARKET

1. How many Propranolol are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Propranolol and key vendor selection criteria
3. Where is Propanolol manufactured? What is the average margin per unit?
4. Market share of Global Propranolol market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Propranolol in-house
6. key predictions for next 5 years in Global Propranolol market
7. Average B-2-B Propranolol market price in all segments
8. Latest trends in Propranolol market, by every market segment
9. The market size (both volume and value) of the Propanolol market in 2024-2030 and every year in between?
10. Production breakup of Propranolol market, by suppliers and their OEM relationship